Filters








8,350 Hits in 7.7 sec

A multi-gene expression profile panel for predicting liver metastasis: An algorithmic approach

Kanisha Shah, Shanaya Patel, Sheefa Mirza, Rakesh M. Rawal, Kapil Mehta
2018 PLoS ONE  
& aim Liver metastasis has been found to affect outcome in prostate, pancreatic and colorectal cancers, but its role in lung cancer is unclear.  ...  Thus, this study aims to generate a model for early diagnosis and timely treatment of liver metastasis in lung cancer patients.  ...  Acknowledgments We would like to thank The Gujarat Cancer & Research Institute and The Gujarat Cancer Society for supporting this work.  ... 
doi:10.1371/journal.pone.0206400 fatcat:rrsg5gvrkjh2lfjyb37aq4wgha

Geraniol suppresses prostate cancer growth through down-regulation of E2F8

Sanghoon Lee, Yu Rang Park, Su-Hwa Kim, Eun-Jung Park, Min Ji Kang, Insuk So, Jung Nyeo Chun, Ju-Hong Jeon
2016 Cancer Medicine  
Clinical relevance of E2F8 in prostate cancer To address the clinical relevance of our findings, we examined the expression levels of E2F8 using microarray datasets of prostate cancer patients (GSE21034  ...  In this study, we performed DNA microarray experiments to explore the molecular mechanisms of antitumor action of geraniol in prostate cancer cells.  ...  Conflict of Interest We hereby declare that we have no pecuniary or other personal interest, direct or indirect, in any matter that raises a conflict.  ... 
doi:10.1002/cam4.864 pmid:27683099 pmcid:PMC5083744 fatcat:pbacwujpnvfy3hsttw7dwqljui

The prostate-cancer metabolome

Cory Abate-Shen, Michael M. Shen
2009 Nature  
(an image of the reduced Planck constant, ħ), noting the transverse correlations between their two light beams.  ...  With the hope of dramatically increased informationstorage capacity, it is likely that quantum images will play an important part in the future of quantum-information processing.  ...  The goal of such investigations is to decipher molecular signatures that distinguish tumours from normal tissues.  ... 
doi:10.1038/457799a pmid:19212391 fatcat:kohcy6apyngill6zbslnohauq4

Insights into Urological Cancer

Claudia Manini, José I. López
2021 Cancers  
The year the Covid-19 pandemic appeared has been quite prolific in urological cancer research, and the collection of articles, perspectives, and reviews on renal, prostate, and urinary tract tumors merged  ...  in this Urological Cancer 2020 issue is just a representative sample of this assertion [...]  ...  The authors concluded that an excess of CPT1A is associated with prostate cancer progression and propose to target lipid catabolic pathways as an alternative therapeutic tool.  ... 
doi:10.3390/cancers13020204 pmid:33429960 fatcat:yg4eggtghndo7b6o6d2fkzb7oi

A Molecular Signature Predictive of Indolent Prostate Cancer

S. Irshad, M. Bansal, M. Castillo-Martin, T. Zheng, A. Aytes, S. Wenske, C. Le Magnen, P. Guarnieri, P. Sumazin, M. C. Benson, M. M. Shen, A. Califano (+1 others)
2013 Science Translational Medicine  
Many newly diagnosed prostate cancers present as low Gleason score tumors that require no treatment intervention.  ...  Using gene set enrichment analysis, we identified a 19-gene signature enriched in indolent prostate tumors.  ...  Notably, we used an unbiased approach based on a decision tree learning algorithm for refinement of an indolence signature to identify a three-gene panel, namely, FGFR1, PMP22, and CDKN1A, which accurately  ... 
doi:10.1126/scitranslmed.3006408 pmid:24027026 pmcid:PMC3943244 fatcat:zmpccrt5mfa75jcfr7pa2vqqpy

Derivation of cancer diagnostic and prognostic signatures from gene expression data

Steve Goodison, Yijun Sun, Virginia Urquidi
2010 Bioanalysis  
The derivation of molecular signatures that can predict tumor recurrence in breast cancer has been a particularly intense area of investigation and a number of studies have shown that molecular signatures  ...  The ability to compare genome-wide expression profiles in human tissue samples has the potential to add an invaluable molecular pathology aspect to the detection and evaluation of multiple diseases.  ...  Goodison) and the Susan Komen Breast Cancer Foundation, BCTR0707587 (Yijun Sun).  ... 
doi:10.4155/bio.10.35 pmid:21083217 pmcid:PMC3058551 fatcat:cs72ku5djncqnn6p75qdyj5doe

Prostate cancer gene expression signature of patients with high body mass index

S Sharad, A Srivastava, S Ravulapalli, P Parker, Y Chen, H Li, G Petrovics, A Dobi
2010 Prostate Cancer and Prostatic Diseases  
The goal of this study was to evaluate prostate cancer gene expression signatures associated with elevated body mass index (BMI).  ...  An additional finding of our study is that some of the obesity related genes were upregulated in tumor-matched normal cells within the high BMI group, when compared to normal cells within the normal BMI  ...  The views expressed in this manuscript are those of the authors and do not reflect the  ... 
doi:10.1038/pcan.2010.44 pmid:21060327 pmcid:PMC3059752 fatcat:3gxxvflg5nennbwpfccxok7fgm

Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach

Yijun Sun, Virginia Urquidi, Steve Goodison
2009 Breast Cancer Research and Treatment  
Analyses identified prognostic signatures that while comprised of only 10-13 genes, significantly outperformed previously reported signatures for breast cancer evaluation.  ...  Previous studies have demonstrated the potential value of gene expression signatures in assessing the risk of post-surgical breast cancer recurrence, however, many of these predictive models have been  ...  Acknowledgments This work was supported in part by the National Cancer Institute under grant NIH/NCI RO1 CA108597 (SG), and Susan Komen Breast Cancer Foundation grant BCTR0707587 (YS).  ... 
doi:10.1007/s10549-009-0365-6 pmid:19291396 pmcid:PMC2844120 fatcat:tsjqjzewhndhlajoi4goi2msdu

Personalized Cancer Care Conference

Kurt Zänker, Enrico Mihich, Hans-Peter Huber, Anne-Lise Borresen-Dale
2013 Journal of Personalized Medicine  
the science-based presentations concerned six scientific areas: (1) Genetic profiling of patients, prediction of risk, late side effects; (2) Molecular profiling of tumors and metastases; (3) Tumor-host  ...  Huber) a program at the cutting edge of -PERSONALIZED CANCER CARE: Risk prediction, early diagnosis, progression and therapy resistance.‖ The conference was held in Oslo from September 7 to 9, 2012 and  ...  and an increased risk of recurrence of breast cancer.  ... 
doi:10.3390/jpm3020070 pmid:25562519 pmcid:PMC4251400 fatcat:q3h4bkvm3rbpriadr347bu6fue

Deregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression

J. L. Chen, J. Li, K. J. Kiriluk, A. M. Rosen, G. P. Paner, T. Antic, Y. A. Lussier, D. J. Vander Griend
2012 Clinical Cancer Research  
Derived gene expression profiles were grouped into cancer biomodules using a protein-protein network algorithm to analyze their relationship to known oncogenes.  ...  Purpose: The aberrant activity of developmental pathways in prostate cancer may provide significant insight into predicting tumor initiation and progression, as well as identifying novel therapeutic targets  ...  Acknowledgments The authors thank the support of the University of Chicago Section of Urology led by Dr. Arieh Shalhav, and the Director of Urologic Research Dr.  ... 
doi:10.1158/1078-0432.ccr-12-0373 pmid:22723371 pmcid:PMC3479663 fatcat:37tywyatfba5rag7gfwpyjfteu

Myc-driven murine prostate cancer shares molecular features with human prostate tumors

Katharine Ellwood-Yen, Thomas G. Graeber, John Wongvipat, M.Luisa Iruela-Arispe, JianFeng Zhang, Robert Matusik, George V. Thomas, Charles L. Sawyers
2003 Cancer Cell  
Human prostate tumor databases revealed modules of human genes that varied in concert with the Myc prostate cancer signature.  ...  These tumors share molecular features with human prostate cancer, as defined by array-based expression profiling, such as loss of the candidate human prostate tumor suppressor gene Nkx3.1 and upregulation  ...  et al., 1995; Pelengaris et al., 1999; An expression signature for Myc-driven murine prostate cancer Watnick et al., 2003) .  ... 
doi:10.1016/s1535-6108(03)00197-1 pmid:14522256 fatcat:j3vyza55xbgibacjozrsatkb6a

Integrative analysis of the cancer transcriptome

Daniel R Rhodes, Arul M Chinnaiyan
2005 Nature Genetics  
DNA microarrays have been widely applied to the study of human cancer, delineating myriad molecular subtypes of cancer, many of which are associated with distinct biological underpinnings, disease progression  ...  These primary analyses have begun to decipher the molecular heterogeneity of cancer, but integrative analyses that evaluate cancer transcriptome data in the context of other data sources are often capable  ...  This work is partially supported by grants from the American Cancer Society and the National Institutes of Health and by the University of Michigan Cancer Center Support Grant.  ... 
doi:10.1038/ng1570 pmid:15920528 fatcat:jsaralzsjvdzrp2qrri25yttde

Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges

Dimitrios Doultsinos, Ian G. Mills
2021 Cancers  
Prostate cancer is a high-incidence cancer that requires improved patient stratification to ensure accurate predictions of risk and treatment response.  ...  Due to the significant contributions of transcription factors and epigenetic regulators to prostate cancer progression, there has been considerable progress made in developing gene signatures that may  ...  Transcription Factors in Prostate Cancer As introduced in the previous section, TFs and epigenetic regulators may affect an array of biological processes/hallmarks of cancer or, instead, have greater bearing  ... 
doi:10.3390/cancers13030495 pmid:33525365 fatcat:22kaa7dnq5dd5czyjp72j5dlr4

Cancer of Unknown Primary: Challenges and Progress in Clinical Management

Noemi Laprovitera, Mattia Riefolo, Elisa Ambrosini, Christiane Klec, Martin Pichler, Manuela Ferracin
2021 Cancers  
Accounting for approximately 3–5% of all cancer diagnoses, CUPs are characterized by an aggressive clinical behavior and represent a real therapeutic challenge.  ...  This disease setting is defined as cancer of unknown primary (CUP).  ...  of genetic findings.  ... 
doi:10.3390/cancers13030451 pmid:33504059 pmcid:PMC7866161 fatcat:ju2ydwuvgjaglfxurmullqry2i

Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy

Efrat Flashner-Abramson, Swetha Vasudevan, Ibukun Adesoji Adejumobi, Amir Sonnenblick, Nataly Kravchenko-Balasha
2019 Theranostics  
We present herein an approach based on information theory that, rather than searches for what makes a tumor similar to other tumors, addresses tumors individually and unbiasedly, and impartially decodes  ...  The challenge has now become to find a way to obtain useful information from these masses of data that will allow to determine which combination of FDA-approved drugs is best suited to treat the specific  ...  We demonstrate the generality of our findings by adding an independent dataset of patients with prostate cancer.  ... 
doi:10.7150/thno.31657 pmid:31410207 pmcid:PMC6691586 fatcat:gxsdntghgngvrace34zy4zeu6y
« Previous Showing results 1 — 15 out of 8,350 results